Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

1st Ebola Patient Diagnosed in the US Has Died

October 8, 2014 12:14 pm | News | Comments

The first Ebola patient diagnosed in the United States died in a Dallas hospital, according to a hospital spokesman. Read more...                                            

TOPICS:

NIH to Study More Than 200 Rare Diseases

October 8, 2014 12:05 pm | News | Comments

Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases. Read more...                          

TOPICS:

Drug Cured 16 of 16 Monkeys with Viral Ebola Relative

October 8, 2014 11:31 am | by Cynthia Fox, Science Editor | Articles | Comments

An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...                   

TOPICS:
Advertisement

Majority of CROs Exchange TMFs Via Outdated Methods

October 8, 2014 11:05 am | News | Comments

The vast majority of contract research organizations (CROs) surveyed lag clinical trial sponsors in how they exchange trial master file (TMF) documents, according to the Veeva 2014 Paperless TMF Survey: The State of CRO TMFs. Read more...

TOPICS:

C3BS Gets Preferred Access from Mayo Clinic

October 8, 2014 10:58 am | News | Comments

Cardio3 BioSciences (C3BS), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announced the signing of a preferred access agreement with Mayo Clinic. Read more...

TOPICS:

'Unsung' Cells Double the Benefits of a New Osteoporosis Drug

October 8, 2014 10:48 am | News | Comments

Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder, according to Johns Hopkins researchers. Read more...

TOPICS:

What Kind of Research Can We Trust?

October 8, 2014 10:40 am | News | Comments

Research involving pharmaceutical company input is notoriously compromised. While not all industry ties lead to biased research, and not all biases are a consequence of industry ties, many studies show industry influence can make drugs look safer and more effective than they really are. Read more...

TOPICS:

3 Win Nobel for Super-Zoom Microscopes

October 8, 2014 10:16 am | by Karl Ritter and Malin Rising | News | Comments

Two Americans and a German scientist won the Nobel Prize in chemistry for finding ways to make microscopes more powerful than previously thought possible, allowing scientists to see how diseases develop inside the tiniest cells. Read more...

TOPICS:
Advertisement

A Universal Ebola Drug Target

October 8, 2014 10:05 am | News | Comments

University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in the online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola. Read more...

TOPICS:

Green Tea-based ‘Missiles’ May Kill Cancer Cells

October 7, 2014 3:31 pm | News | Comments

Green tea has long been known for its anti-oxidant, anti-cancer, anti-aging and anti-microbial properties. A group of researchers from the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR has taken the health benefits of green tea to the next level by using one of its ingredients to develop a drug delivery system, which kills cancer cells more efficiently. Read more...

TOPICS:

Manzo Pharmaceuticals' Probiotic Will Not Need FDA Approval

October 7, 2014 3:05 pm | News | Comments

Manzo Pharmaceuticals Inc. announced that after discussions with the FDA, it has been determined that its long lasting lactose digestive aid, Lacto-Freedom, will not need FDA approval to be released to the public. Read more...           

TOPICS:

BMS Won't Pursue FDA Approval for HCV Treatment

October 7, 2014 2:56 pm | News | Comments

Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration (FDA) approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application (NDA) for asunaprevir. Read more...

TOPICS:

FDA Grants Fast Track Designation to NurOwn for the Treatment of ALS

October 7, 2014 2:45 pm | News | Comments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). Read more...

TOPICS:

A New Pathway Discovered Regulating Autoimmune Diseases

October 7, 2014 2:32 pm | News | Comments

The main function of the immune system is to protect against diseases and infections. For unknown reasons our immune system attacks healthy cells, tissues and organs in a process called autoimmunity, which can result in diseases such as multiple sclerosis, type 1 diabetes, lupus or rheumatoid arthritis. There are currently no existing cures for these diseases. Read more...

TOPICS:

Vivolux Cancer Drug Receives FDA Clearance for Clinical Study

October 7, 2014 2:21 pm | News | Comments

Vivolux, a pharmaceutical company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX1570 to clinical phase 1/2 for treatment against relapsed and/or refractory multiple myeloma. Read more...        

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading